{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:41:55Z","timestamp":1770730915757,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006335","name":"Covenant University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006335","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2025.101089","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:06:54Z","timestamp":1767114414000},"page":"101089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unraveling the potential of USP8 as a therapeutic target for overcoming c-Met-mediated resistance in breast cancer: A review"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9808-2297","authenticated-orcid":false,"given":"Doris Nnenna","family":"Amuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-0937","authenticated-orcid":false,"given":"Suleiman","family":"Zakari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayomikun Joshua","family":"Pirisola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4209-7898","authenticated-orcid":false,"given":"Olubanke Olujoke","family":"Ogunlana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeka E.J.","family":"Iweala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.101089_bib0001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/1596-3519.356811","article-title":"Haptoglobin genotypes and malaria comorbidity in breast cancer and healthy Nigerian women","volume":"21","author":"Dokunmu","year":"2022","journal-title":"Ann. Afr. Med."},{"key":"10.1016\/j.ctarc.2025.101089_bib0002","doi-asserted-by":"crossref","DOI":"10.1200\/GO.23.00135","article-title":"Breast cancer phenotypes in Africa: a scoping review and meta-analysis","author":"Onyia","year":"2023","journal-title":"JCo Glob. Oncol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.856974","article-title":"Breast cancer stem-like cells in drug resistance: a review of mechanisms and novel therapeutic strategies to overcome drug resistance","volume":"12","author":"Saha","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0004","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"BJR"},{"key":"10.1016\/j.ctarc.2025.101089_bib0005","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.7150\/thno.49922","article-title":"Managing therapeutic resistance in breast cancer: from the lncRNAs perspective","volume":"10","author":"Peng","year":"2020","journal-title":"Theranostics."},{"key":"10.1016\/j.ctarc.2025.101089_bib0006","article-title":"Chemotherapeutic resistance genes of breast cancer patients \u2013 an overview","volume":"1","author":"Ajith","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.ctarc.2025.101089_bib0007","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3389\/fonc.2019.01377","article-title":"Aberrant RON and MET Co-overexpression as novel prognostic biomarkers of shortened patient survival and therapeutic targets of tyrosine kinase inhibitors in pancreatic cancer","volume":"9","author":"Hu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0008","doi-asserted-by":"crossref","first-page":"9170","DOI":"10.3390\/ijms21239170","article-title":"Targeting HGF\/c-MET axis in pancreatic cancer","volume":"21","author":"Pothula","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.101089_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1074\/jbc.RA119.011341","article-title":"Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding","volume":"295","author":"Park","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2025.101089_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","article-title":"Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene","volume":"3","author":"Pennacchietti","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctarc.2025.101089_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.629422","article-title":"The hypoxic microenvironment of breast cancer cells promotes resistance in radiation therapy","volume":"10","author":"Gilreath","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0012","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4143\/crt.2018.052","article-title":"Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor Capmatinib","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2025.101089_bib0013","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0014","series-title":"C-Met As a Potential Therapeutic Target in Triple Negative Breast cancer. Cancer-Leading Proteases [Internet]","first-page":"295","author":"Chaudhary","year":"2020"},{"key":"10.1016\/j.ctarc.2025.101089_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-022-01503-1","article-title":"Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer","volume":"21","author":"Raj","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ctarc.2025.101089_bib0016","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12935-022-02658-z","article-title":"Anti-cancer therapeutic strategies based on HGF\/MET, EpCAM, and tumor-stromal cross talk","volume":"22","author":"Barzaman","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ctarc.2025.101089_bib0017","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03bab, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12935-022-02658-z","article-title":"Anti-cancer therapeutic strategies based on HGF\/MET, EpCAM, and tumor-stromal cross talk","volume":"22","author":"Barzaman","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ctarc.2025.101089_bib0019","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-015-0547-6","article-title":"The clinical and functional significance of c-Met in breast cancer: a review","volume":"17","author":"Ho-Yen","year":"2015","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0020","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1038\/s41467-021-24367-3","article-title":"Structural basis of the activation of c-MET receptor","volume":"12","author":"Uchikawa","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2025.101089_bib0021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/BST20200394","article-title":"State of the structure address on MET receptor activation by HGF","volume":"49","author":"Linossi","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ctarc.2025.101089_bib0022","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13058-024-01768-y","article-title":"c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"26","author":"Park","year":"2024","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0023","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/biomedicines3010046","article-title":"c-met and other cell surface molecules: interaction, activation and functional consequences","volume":"3","author":"Viticchi\u00e8","year":"2015","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctarc.2025.101089_bib0024","article-title":"Beta 1-integrin\u2013c-met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes","volume":"7","author":"Barrow-McGee","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2025.101089_bib0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/medicina58050649","article-title":"Therapeutic strategies for ovarian cancer in point of HGF\/c-MET targeting","volume":"58","author":"Kim","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.ctarc.2025.101089_bib0026","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.3390\/jcm11236987","article-title":"Expression of c-MET in estrogen receptor positive and HER2 negative resected breast cancer correlated with a poor prognosis","volume":"11","author":"Iovino","year":"2022","journal-title":"JCM"},{"key":"10.1016\/j.ctarc.2025.101089_bib0027","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clbc.2014.06.001","article-title":"Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit","volume":"14","author":"De Melo Gagliato","year":"2014","journal-title":"Clin. Breast. Cancer"},{"key":"10.1016\/j.ctarc.2025.101089_bib0028","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/apm.13031","article-title":"Tumour angiogenesis and c-met pathway activation \u2013 implications in breast cancer","volume":"128","author":"Mitra","year":"2020","journal-title":"APMIS"},{"key":"10.1016\/j.ctarc.2025.101089_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.719217","article-title":"The significance of MET expression and strategies of targeting MET treatment in advanced gastric cancer","volume":"11","author":"Liao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0030","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","article-title":"Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells","volume":"68","author":"Shattuck","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0031","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/mol.114.096065","article-title":"The c-MET\/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP\/ABCG2 expression","volume":"87","author":"Jung","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0032","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1158\/0008-5472.CAN-14-2743","article-title":"c-myc alterations confer therapeutic response and acquired resistance to c-met inhibitors in MET-addicted cancers","volume":"75","author":"Shen","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0033","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/mc.23878","article-title":"HGF\/c-met promotes breast cancer tamoxifen resistance through the EZH2\/HOTAIR-miR-141\/200a feedback signaling pathway","volume":"64","author":"Lai","year":"2025","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ctarc.2025.101089_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246201","article-title":"Vascular niche facilitates acquired drug resistance to c-met inhibitor in originally sensitive osteosarcoma cells","volume":"14","author":"Tang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2025.101089_bib0035","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1158\/1538-7445.AM2024-4555","article-title":"Abstract 4555: c-met\/AXL crosstalk in mediating therapeutic resistance in renal cell carcinoma","volume":"84","author":"Sabarwal","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0036","first-page":"896","article-title":"ETS-1\/c-met drives resistance to sorafenib in hepatocellular carcinoma","volume":"15","author":"Ma","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0037","article-title":"Cancer biology and therapeutics: navigating recent advances and charting future directions","volume":"7","author":"Cleanclay","year":"2023","journal-title":"TJNPR"},{"key":"10.1016\/j.ctarc.2025.101089_bib0038","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/cr.2016.35","article-title":"E2 enzymes: more than just middle men","volume":"26","author":"Stewart","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0039","first-page":"1","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020"},{"key":"10.1016\/j.ctarc.2025.101089_bib0040","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1042\/BST20190527","article-title":"Ubiquitin-specific protease 8 (USP8\/UBPy): a prototypic multidomain deubiquitinating enzyme with pleiotropic functions","volume":"47","author":"Dufner","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ctarc.2025.101089_bib0041","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1074\/jbc.RA119.011341","article-title":"Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding","volume":"295","author":"Park","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2025.101089_bib0042","article-title":"The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics","volume":"701","author":"MdT","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ctarc.2025.101089_bib0043","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.2147\/CMAR.S300195","article-title":"USP8 is a novel therapeutic target in melanoma through regulating receptor tyrosine kinase levels","volume":"13","author":"Duan","year":"2021","journal-title":"CMAR"},{"key":"10.1016\/j.ctarc.2025.101089_bib0044","doi-asserted-by":"crossref","first-page":"34909","DOI":"10.1074\/jbc.M109.016287","article-title":"Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8\u00b7STAM complex","volume":"285","author":"Berlin","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2025.101089_bib0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41418-019-0419-1","article-title":"Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer","volume":"27","author":"Shin","year":"2020","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.ctarc.2025.101089_bib0046","doi-asserted-by":"crossref","first-page":"14999","DOI":"10.18632\/aging.203061","article-title":"Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases","volume":"13","author":"Zhu","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.ctarc.2025.101089_bib0047","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/ph15050633","article-title":"Artonin F induces the ubiquitin-proteasomal degradation of c-met and decreases akt-mTOR signaling","volume":"15","author":"Soonnarong","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ctarc.2025.101089_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2024.100204","article-title":"Targeting c-met in breast cancer: from mechanisms of chemoresistance to novel therapeutic strategies","volume":"7","author":"Iweala","year":"2024","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.ctarc.2025.101089_bib0049","first-page":"251","article-title":"Inhibition of ubiquitin specific peptidase 8 is effective against 5-fluorouracil resistance in colon cancer via suppressing EGFR and EGFR-mediated signaling pathways","volume":"39","author":"Xi","year":"2024","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.ctarc.2025.101089_bib0050","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41418-022-01102-z","article-title":"Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer","volume":"30","author":"Yang","year":"2023","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.ctarc.2025.101089_bib0051","doi-asserted-by":"crossref","first-page":"57","DOI":"10.15430\/JCP.2015.20.1.57","article-title":"Inhibition of ubiquitin-specific peptidase 8 suppresses growth of gefitinib-resistant non-small cell lung cancer cells by inducing apoptosis","volume":"20","author":"Jeong","year":"2015","journal-title":"J. Cancer Prev."},{"key":"10.1016\/j.ctarc.2025.101089_bib0052","doi-asserted-by":"crossref","first-page":"8914","DOI":"10.1021\/acs.jmedchem.2c00013","article-title":"Discovery of potent small-molecule USP8 inhibitors for the treatment of breast cancer through regulating er\u03b1 expression","volume":"65","author":"Tian","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101089_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116275","article-title":"The discovery of potent USP2\/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364","volume":"268","author":"Tian","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ctarc.2025.101089_bib0054","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1538-7445.AM2015-662","article-title":"Abstract 662: USP8 modulates ubiquitination of LRIG1 for met degradation","volume":"75","author":"Lee","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101089_bib0055","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108791","article-title":"USP8 promotes cancer progression and extracellular vesicle-mediated CD8+T cell exhaustion by deubiquitinating the TGF -\u03b2 receptor t\u03b2rii","volume":"41","author":"Xie","year":"2022","journal-title":"EMBO J."},{"key":"10.1016\/j.ctarc.2025.101089_bib0056","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108791","article-title":"USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-\u03b2 receptor t\u03b2rii","volume":"41","author":"Xie","year":"2022","journal-title":"EMBO J."},{"key":"10.1016\/j.ctarc.2025.101089_bib0057","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/biom15020240","article-title":"Ubiquitin-specific protease inhibitors for cancer therapy: recent advances and future prospects","volume":"15","author":"Bakkar","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ctarc.2025.101089_bib0058","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.3390\/ijms22094546","article-title":"Advances in the development ubiquitin-specific peptidase (USP) inhibitors","volume":"22","author":"Chen","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.ctarc.2025.101089_bib0059","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/8483325","article-title":"Ubiquitin-specific peptidase 8 modulates cell proliferation and induces cell cycle arrest and apoptosis in breast cancer by stabilizing estrogen receptor alpha","volume":"2023","author":"Zheng","year":"2023","journal-title":"J. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225002242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225002242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:55:29Z","timestamp":1770656129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225002242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":59,"alternative-id":["S2468294225002242"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101089","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the potential of USP8 as a therapeutic target for overcoming c-Met-mediated resistance in breast cancer: A review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101089"}}